-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Chemours, Lowers Price Target to $15

Benzinga·11/04/2026 23:17:07
Listen to the news
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $16 to $15.